Danaher Co. (NYSE:DHR) Stake Reduced by Western Wealth Management LLC

Western Wealth Management LLC cut its holdings in Danaher Co. (NYSE:DHR) by 3.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,759 shares of the conglomerate’s stock after selling 231 shares during the quarter. Western Wealth Management LLC’s holdings in Danaher were worth $1,332,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. BKM Wealth Management LLC purchased a new position in Danaher in the 4th quarter worth about $27,000. OFI Invest Asset Management purchased a new position in Danaher in the 3rd quarter worth about $30,000. First Capital Advisors Group LLC. purchased a new position in Danaher in the 2nd quarter worth about $32,000. BOK Financial Private Wealth Inc. purchased a new position in Danaher in the 3rd quarter worth about $34,000. Finally, Nalls Sherbakoff Group LLC purchased a new position in Danaher during the 3rd quarter valued at about $37,000. 79.05% of the stock is currently owned by institutional investors.

Insider Transactions at Danaher

In related news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Teri List sold 3,289 shares of the company’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now owns 38,102 shares of the company’s stock, valued at $9,601,704. The disclosure for this sale can be found here. Insiders sold a total of 32,957 shares of company stock worth $8,265,802 over the last three months. 11.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Citigroup lifted their target price on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. HSBC raised Danaher from a “hold” rating to a “buy” rating and boosted their price target for the company from $250.00 to $280.00 in a research note on Wednesday. Raymond James boosted their price target on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, KeyCorp boosted their price target on Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $268.27.

Danaher Stock Down 0.4 %

Shares of DHR stock opened at $235.37 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $259.00. The firm has a market cap of $174.30 billion, a PE ratio of 36.83, a price-to-earnings-growth ratio of 3.59 and a beta of 0.83. The stock has a 50 day moving average of $248.94 and a 200-day moving average of $230.05. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company had revenue of $6.41 billion during the quarter, compared to analyst estimates of $6.10 billion. During the same period in the previous year, the company earned $2.87 earnings per share. The company’s quarterly revenue was down 10.2% compared to the same quarter last year. On average, equities analysts predict that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a dividend of $0.27 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.46%. Danaher’s payout ratio is 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.